Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped down before the market opened on Thursday. The stock had previously closed at $31.16, but opened at $29.99. Nanobiotix shares last traded at $29.8790, with a volume of 9,803 shares changing hands.

Analysts Set New Price Targets

NBTX has been the subject of several recent analyst reports. Guggenheim initiated coverage on Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Finally, Leerink Partners lifted their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Stock Performance

The stock has a 50-day moving average price of $38.32 and a 200-day moving average price of $37.29.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.